with a wide spectrum of activity (2, 4, 6, 11, 12; F. Gudiol, X. Ariza, J. Linares, and C. Dominguez, Program Abstr. Int. Congr. Chemother. 12th, Florence, Italy, abstr. no. 911, 1981) . It is more active than presently available cephalosporins against a variety of aerobic gram-negative rods. The present study was designed to determine the safety and efficacy of moxalactam in the treatment of hospitalized patients with serious infections. Susceptibility testing. Disk susceptibility testing for all aerobic isolates was performed with 30-,ug disks of moxalactam by the method of Bauer et al (3) . In addition, the minimum inhibitory concentrations (MICs) of moxalactam for some isolates were determined by the microtiter broth dilution method (5) . Calcium-and magnesium-supplemented Mueller-Hinton broth was used for the MIC testing with an inoculum size of 101 colony-forming units per ml. For streptococcal MICs the broth was supplemented with lysed horse blood. We determined minimal bactericidal concentrations by removing a sample of broth from every well showing no visible growth and inoculating it onto sheep blood agar (5) . All plates were incubated for 48 h at 35°C. For anaerobic isolates the MICs were determined in groups of 20 by the agar dilution technique (7) . Serial twofold dilutions (256 to 0.125 ,ug/ml) were prepared in Brucella agar (Difco Laboratories) supplemented with 5% sheep blood and vitamin K. All plates were reduced anaerobically overnight before inoculation. Each Criteria for judging responses. We defined clinical cure as findings resolved with no evidence of infection at the time treatment was discontinued and during the follow-up period. We defined clinical failure as an unsatisfactory clinical response. Superinfection was the appearance of a new pathogen associated with signs and symptoms of a new infection at any site.
RESULTS
Of 82 patients entered into this study, 15 were considered non-evaluable; 9 of these showed no pretreatment pathogen, 1 yielded inadequate data, 1 required premature termination due to adverse experience, 1 had a resistant pretreatment isolate, and 3 had received concomitant administration of other antibiotics. The adverse experience occurred in a patient with chronic osteomyelitis secondary to infection with Alcaligenes faecalis, Staphylococcus epidermidis and B. melaninogenicus. The patient received 2 g of moxalactam intravenously (i.v.) every 8 h (q8h). On day 7 he developed a rash and fever, and the moxalactam was discontinued. He was improving at this time. The resistant pretreatment isolate was recovered from a patient with Pseudomonas aeruginosa osteomyelitis. The patient was begun on 3 g of moxalactam i.v. q8h at the time of surgical debridement. On day 2 the moxalactam was discontinued, when a resistant P. aeruginosa strain (MIC, 64 ,ug/ml) was identified in the bone specimen. The patient was not responding clinically at this time.
We considered 67 patients to be evaluable.
There were 17 males and 50 females. Age ranged from 16 to 88 (median, 25 years). Infection diagnosis and treatment are summarized in Table 1.
A total of 32 patients had endometritis or chorioamnionitis. These infections followed Cesarean sections or premature rupture of the membranes. Clinical diagnosis was based on fever, uterine tenderness, and, in some cases, foul-smelling vaginal discharge. Bacteriological diagnosis was based on cultures of endometrium, amniotic fluid, vaginal discharge, or peritoneal fluid. Bacteria isolated from these patients included 83 aerobes and 67 anaerobes. The leading aerobic isolates were group B streptococci (5 isolates), enterococci (5 isolates), and other streptococci (20 isolates). The leading anaerobic isolates were B. melaninogenicus (14 isolates) and other Bacteroides species (30 isolates). Six patients were bacteremic. Blood culture isolates included two of streptococci, two of peptococci, one of Sarcina ventriculi, and one of Fusobacterium sp. There was an average of two anaerobic and two aerobic isolates per patient. All patients were treated with 2 g of moxalactam i.v. q8h except for two who received 1 g intramuscularly q8h. Treatment was continued for 3 to There were five patients with urinary tract infections. Two were bacteremic. These two patients were given 1 and 2 g of moxalactam i.v. q8h for 12 and 14 days, respectively. The patients without bacteremia were given 1 g of moxalactam i.v. q8h for 7 to 14 days. Urine isolates included E. coli in four cases and E. coli and Hafnia alvei in one case. Follow-up urine cultures 5 to 9 days later were negative in all patients.
There were two patients with bacteremia from an unknown source. One of these patients had metastatic hepatocellular carcinoma. K. pneumoniae was isolated from the blood over a 3-day period. The patient continued to be bacteremic on penicillin G and tobramycin. He was treated with 4 g of moxalactam i.v. q8h for 8 days. Follow-up blood cultures were negative. The second patient was a 64-year-old paraplegic with multiple chronic severe decubiti and bacteremia secondary to S. epidermidis infection (MIC, 16 ,ug/ml). Multiple blood cultures were positive. He was treated with 2 g of moxalactam i.v. q8h for 21 days. At this time he developed signs of sepsis. Enterococcus (MIC, >128 ,ug/ml) and Clostridium tertium (MIC, 8 ,ug/ml) were isolated from the blood. The patient was switched to ampicillin and recovered.
The patient with endocarditis had multiple blood cultures positive for S. aureus (MIC, 2 ,ug/ ml). She was a 17-year-old with mental retardation and possible rheumatic heart disease. She was treated with 2 g of moxalactam i.v. q8h for 28 days. Follow-up blood cultures 2 and 6 months after the completion of therapy were negative. The patient with peritonitis had mixed flora, including an enterococcus, non-A, non-B, non-D streptococci, P. aeruginosa, Klebsiella oxytoca, Bacteroides fragilis, Fusobacterium nucleatum, and Veillonella spp., isolated from peritoneal fluid. The infection followed rupture of a retrocecal appendix. He was treated with surgical drainage and 4 g of moxalactam i.v. q8h for 11 days, with complete resolution of the infection.
The results of susceptibility testing are shown in Table 2 . An MIC of .64 (resistant) was seen in 6 of 125 (5%) isolates tested. The resistant anaerobes were all isolated from endometritis cases as part of mixed flora. All of these patients were cured clinically. The resistant S. aureus was isolated from a patient with periorbital cellulitis. Aspirates of material from this area Gaffkya spp. 6 6 were positive for K. pneumoniae, E. coli, group A streptococci, and the resistant S. aureus. The patient was treated with 2 g of moxalactam i.v. q8h for 11 days and was cured clinically. The susceptibility of aerobic isolates from the patients with endometritis and chorioamnionitis was measured by disk diffusion testing only. A zone of inhibition of <14 mm (resistant) was seen in 5 of 63 (8%) isolates tested. All of these resistant isolates were enterococci. They were isolated as part of mixed endometrial flora. London, abstract, 1981) . This phenomenon has been associated with general debility, malnutrition, liver or biliary duct disease, coagulopathies, and severe reduced renal function which leads to excessive serum levels. The prophylactic administration of vitamin K to high-risk patients has been recommended by the Lilly Research Laboratories (personal communication).
There was one patient with enterococcal and clostridial superinfection. Enterococcal superinfection has been noted by others in the present clinical trials of moxalactam (11, 12 ; R. C. Moellering, Jr., Moxalactam Symp., London, abstract, 1981). Enterococci are resistant to moxalactam and all cephalosporins and may cause superinfection in patients treated with any of these antibiotics. The overall risk, based on preliminary data, is low.
We conclude that moxalactam is an effective and safe antibiotic and can be used in a variety of serious infections.
